$453bn AUM as of March 2025; 2,300+ employees in 29 offices across four continents. Global alternatives manager: Global Private Equity, Global Credit, Global Investment Solutions; 300+ active investment vehicles. 289 acquisitions across sectors incl. GRC Software, IT Services, Investment Tech; avg deal size $2.57bn. Notable recent: bluebird bio (gene therapy, June 2025), Vantive (kidney care, $3.8bn, Aug 2024), The Very Group (retail/fintech, Nov 2025). Strong real estate presence via Metropolitan Real Estate fund-of-funds.
Investment Focus
Investment Thesis
Sector specialization, operational value creation, disciplined underwriting across buyout, growth, real assets, credit, secondaries—mid-teens net IRR & 1.7–2.0x MOIC targets. Sector-specialist investor leveraging global scale & operating expertise to drive value through operational improvement, buy-and-build M&A, cross-border expansion with disciplined entry valuations. 2023 reweighting: away from consumer/media/retail toward financial services, healthcare, technology, industrials, government services. Focus: control buyouts & growth equity. Geography: 37 acquisition countries. Avoids: early-stage venture, highly volatile micro-cap sectors.
Interested in connecting?
Visit their website or reach out directly.